Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

BACKGROUND Nonselective beta-adrenergic blockers decrease portal pressure and prevent variceal hemorrhage. Their effectiveness in preventing varices is unknown. METHODS We randomly assigned 213 patients with cirrhosis and portal hypertension (minimal hepatic venous pressure gradient [HVPG] of 6 mm Hg) to receive timolol, a nonselective beta-blocker (108 patients), or placebo (105 patients). The primary end point was the development of gastroesophageal varices or variceal hemorrhage. Endoscopy and HVPG measurements were repeated yearly. RESULTS During a median follow-up of 54.9 months, the rate of the primary end point did not differ significantly between the timolol group and the placebo group (39 percent and 40 percent, respectively; P=0.89), nor were there significant differences in the rates of ascites, encephalopathy, liver transplantation, or death. Serious adverse events were more common among patients in the timolol group than among those in the placebo group (18 percent vs. 6 percent, P=0.006). Varices developed less frequently among patients with a baseline HVPG of less than 10 mm Hg and among those in whom the HVPG decreased by more than 10 percent at one year and more frequently among those in whom the HVPG increased by more than 10 percent at one year. CONCLUSIONS Nonselective beta-blockers are ineffective in preventing varices in unselected patients with cirrhosis and portal hypertension and are associated with an increased number of adverse events. (ClinicalTrials.gov number, NCT00006398.)

[1]  R. Groszmann,et al.  Effect of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model. , 1985, Gastroenterology.

[2]  D. Roulot,et al.  Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. , 1988, Journal of hepatology.

[3]  R. Groszmann,et al.  The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. , 1997, Gastroenterology.

[4]  J. Rodés,et al.  Hemodynamic response to pharmacological treatment of portal hypertension and long‐term prognosis of cirrhosis , 2003, Hepatology.

[5]  J. Rodés,et al.  Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis , 1995, The Lancet.

[6]  R. Groszmann,et al.  Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. , 1991, The Journal of clinical investigation.

[7]  A. Gimson,et al.  A controlled trial of oral propranolol compared with injection sclerotherapy for the long‐term magnagement of variceal bleeding , 1990, Hepatology.

[8]  R. de Franchis,et al.  Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. , 2002, Journal of hepatology.

[9]  Y. Liaw,et al.  Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. , 2008, Liver.

[10]  X. Cussó,et al.  Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. , 1996, The New England journal of medicine.

[11]  R. Groszmann,et al.  Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. , 1996, Gastroenterology.

[12]  E. Christensen,et al.  Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone. , 1981, Gastroenterology.

[13]  J. Calleja,et al.  Propranolol plus placebo versus propranolol plus isosorbide‐5‐mononitrate in the prevention of a first variceal bleed: A double‐blind RCT , 2003, Hepatology.

[14]  P. Calès,et al.  Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. , 1987, The New England journal of medicine.

[15]  B. González,et al.  291 Hemodynamic response to beta-blockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis , 2003 .

[16]  T. Ishizaki,et al.  Comparison of disposition and effect of timolol and propranolol on exercise tachycardia , 1978, European Journal of Clinical Pharmacology.

[17]  A. Ravaud,et al.  Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. , 1990, Gut.

[18]  P. Amodio,et al.  Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis , 1996, The Lancet.

[19]  D. Valla,et al.  Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. , 1999, European journal of gastroenterology & hepatology.

[20]  P. Korner,et al.  COMPARISON OF EFFECTIVENESS OF TIMOLOL ADMINISTERED ONCE A DAY AND TWICE A DAY IN THE CONTROL OF BLOOD PRESSURE IN ESSENTIAL HYPERTENSION , 1979, The Medical journal of Australia.

[21]  F. Nevens Diagnosis of Portal Hypertension: How and When , 2001 .

[22]  R. Groszmann,et al.  The hepatic venous pressure gradient: Anything worth doing should be done right , 2004, Hepatology.

[23]  J. Boadas,et al.  Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. , 2001, The New England journal of medicine.

[24]  P. Angeli,et al.  A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. , 2004, Gastroenterology.

[25]  R. Groszmann,et al.  Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. , 1990, Gastroenterology.

[26]  R. Terg,et al.  Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study , 2003, Hepatology.

[27]  R. Groszmann,et al.  Short‐term effects of propranolol on portal venous pressure , 1986, Hepatology.

[28]  M. Kaplan Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: A randomized multicenter trial , 1991 .

[29]  M. Brown,et al.  (--)-Timolol is a more potent antagonist of the positive inotropic effects of (--)-adrenaline than of those of (--)-noradrenaline in human atrium. , 1996, British journal of clinical pharmacology.

[30]  G. D’Amico,et al.  Pharmacological Treatment of Portal Hypertension: An Evidence-Based Approach , 1999, Seminars in liver disease.

[31]  R. Groszmann,et al.  Increased portal venous resistance hinders portal pressure reduction during the administration of β‐adrenergic blocking agents in a portal hypertensive model , 1985, Hepatology.

[32]  L. Capocaccia,et al.  Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. , 1997, Gastroenterology.